Cardiol Therapeutics (TSE:CRDL) Stock Price Down 2.2%

Cardiol Therapeutics Inc. (TSE:CRDL – Get Rating)’s stock price traded down 2.2% during mid-day trading on Wednesday . The company traded as low as C$0.89 and last traded at C$0.89. 34,625 shares changed hands during trading, a decline of 52% from the average session volume of 72,107 shares. The stock had previously closed at C$0.91.

Cardiol Therapeutics Stock Performance

The company has a market cap of C$58.97 million, a PE ratio of -1.64 and a beta of 0.92. The company has a current ratio of 6.27, a quick ratio of 6.84 and a debt-to-equity ratio of 0.14. The business has a fifty day moving average of C$0.76 and a 200-day moving average of C$0.78.

Cardiol Therapeutics Company Profile

(Get Rating)

Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis.